Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLPT NASDAQ:DRTS NASDAQ:NPCE NASDAQ:OBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLPTClearPoint Neuro$19.74+2.4%$11.21$9.76▼$21.57$548.08M0.89893,440 shs3.75 million shsDRTSAlpha Tau Medical$4.16+2.5%$3.41$2.11▼$4.39$344.37M161,332 shs96,850 shsNPCENeuroPace$10.01-2.1%$9.26$5.45▼$18.98$338.09M1.9178,991 shs130,862 shsOBIOOrchestra BioMed$2.43+0.4%$2.73$2.20▼$6.50$93.52M0.61209,257 shs235,650 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLPTClearPoint Neuro+2.39%+73.92%+85.53%+67.29%+75.16%DRTSAlpha Tau Medical+2.46%+9.19%+25.30%+39.60%+79.31%NPCENeuroPace-2.05%-3.00%+11.59%-6.54%+49.18%OBIOOrchestra BioMed+0.41%-3.19%-19.00%-12.59%-48.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLPTClearPoint Neuro$19.74+2.4%$11.21$9.76▼$21.57$548.08M0.89893,440 shs3.75 million shsDRTSAlpha Tau Medical$4.16+2.5%$3.41$2.11▼$4.39$344.37M161,332 shs96,850 shsNPCENeuroPace$10.01-2.1%$9.26$5.45▼$18.98$338.09M1.9178,991 shs130,862 shsOBIOOrchestra BioMed$2.43+0.4%$2.73$2.20▼$6.50$93.52M0.61209,257 shs235,650 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLPTClearPoint Neuro+2.39%+73.92%+85.53%+67.29%+75.16%DRTSAlpha Tau Medical+2.46%+9.19%+25.30%+39.60%+79.31%NPCENeuroPace-2.05%-3.00%+11.59%-6.54%+49.18%OBIOOrchestra BioMed+0.41%-3.19%-19.00%-12.59%-48.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLPTClearPoint Neuro 3.00Buy$19.67-0.37% DownsideDRTSAlpha Tau Medical 3.00Buy$9.00116.35% UpsideNPCENeuroPace 2.83Moderate Buy$16.6065.83% UpsideOBIOOrchestra BioMed 3.00Buy$13.50455.56% UpsideCurrent Analyst Ratings BreakdownLatest OBIO, DRTS, CLPT, and NPCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.009/3/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/20/2025OBIOOrchestra BioMedBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral8/13/2025NPCENeuroPaceZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025NPCENeuroPaceWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$17.00 ➝ $15.008/13/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/7/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/1/2025CLPTClearPoint NeuroStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $9.00(Data available from 9/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLPTClearPoint Neuro$31.39M17.88N/AN/A$0.92 per share21.46DRTSAlpha Tau MedicalN/AN/AN/AN/A$0.89 per shareN/ANPCENeuroPace$79.91M4.14N/AN/A$0.27 per share37.07OBIOOrchestra BioMed$2.64M35.57N/AN/A$0.87 per share2.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLPTClearPoint Neuro-$18.91M-$0.81N/AN/AN/A-66.15%-94.44%-51.58%11/6/2025 (Estimated)DRTSAlpha Tau Medical-$31.75M-$0.48N/AN/AN/AN/A-51.21%-38.18%11/18/2025 (Estimated)NPCENeuroPace-$27.14M-$0.84N/AN/AN/A-29.29%-168.61%-25.48%11/11/2025 (Estimated)OBIOOrchestra BioMed-$61.02M-$1.83N/AN/AN/A-2,367.49%-289.42%-110.04%11/11/2025 (Estimated)Latest OBIO, DRTS, CLPT, and NPCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CLPTClearPoint Neuro-$0.20-$0.21-$0.01-$0.21$9.20 million$9.22 million8/12/2025Q2 2025NPCENeuroPace-$0.24-$0.26-$0.02-$0.26$23.08 million$23.52 million8/12/2025Q2 2025OBIOOrchestra BioMed-$0.51-$0.50+$0.01-$0.50$0.78 million$0.84 million8/11/2025Q2 2025DRTSAlpha Tau Medical-$0.12-$0.13-$0.01-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLPTClearPoint NeuroN/AN/AN/AN/AN/ADRTSAlpha Tau MedicalN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLPTClearPoint Neuro1.467.306.45DRTSAlpha Tau Medical0.0710.525.81NPCENeuroPace3.025.474.51OBIOOrchestra BioMed48.762.102.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLPTClearPoint Neuro30.08%DRTSAlpha Tau Medical2.65%NPCENeuroPace78.83%OBIOOrchestra BioMed53.20%Insider OwnershipCompanyInsider OwnershipCLPTClearPoint Neuro6.97%DRTSAlpha Tau Medical39.50%NPCENeuroPace20.50%OBIOOrchestra BioMed8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLPTClearPoint Neuro11028.43 million26.45 millionOptionableDRTSAlpha Tau Medical8084.82 million51.32 millionNo DataNPCENeuroPace17033.08 million26.30 millionOptionableOBIOOrchestra BioMed438.64 million35.51 millionNot OptionableOBIO, DRTS, CLPT, and NPCE HeadlinesRecent News About These CompaniesOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Rating of "Buy" by AnalystsSeptember 25 at 2:43 AM | marketbeat.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Short Interest Up 37.2% in AugustSeptember 17, 2025 | marketbeat.comHC Wainwright Expects Higher Earnings for Orchestra BioMedSeptember 9, 2025 | marketbeat.comOrchestra BioMed announces new data from AVIM therapy programSeptember 4, 2025 | msn.comOrchestra BioMed price target lowered to $10 from $12 at H.C. WainwrightSeptember 4, 2025 | msn.comOrchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation ...September 4, 2025 | markets.businessinsider.comOrchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following WashoutSeptember 4, 2025 | globenewswire.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Average Rating of "Buy" from AnalystsSeptember 1, 2025 | marketbeat.comInsider Buying: Orchestra BioMed (NASDAQ:OBIO) Insider Acquires 6,000 Shares of StockAugust 27, 2025 | marketbeat.comOrchestra BioMed (NASDAQ:OBIO) Director Purchases $15,033.60 in StockAugust 27, 2025 | marketbeat.comOrchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure ...August 26, 2025 | bakersfield.comBOrchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical ElectrophysiologyAugust 26, 2025 | globenewswire.comInsider Buying: Orchestra BioMed (NASDAQ:OBIO) Insider Acquires 6,000 Shares of StockAugust 26, 2025 | insidertrades.comBTIG Downgrades Orchestra BioMed Holdings (OBIO)August 21, 2025 | msn.comOrchestra BioMed downgraded to Neutral from Buy at BTIGAugust 20, 2025 | msn.comOrchestra BioMed Reports Q2 2025 Financial ResultsAugust 19, 2025 | msn.comOrchestra BioMed Study Shows AVIM Therapy Could Transform Care for Hypertensive Heart DiseaseAugust 17, 2025 | msn.comOrchestra BioMed Secures $111M to Advance Late-Stage Cardiac Therapies, Hits Multiple FDA MilestonesAugust 15, 2025 | msn.comOrchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic DysfunctionAugust 14, 2025 | globenewswire.comOrchestra BioMed reports Q2 EPS (50c), consensus (51c)August 12, 2025 | msn.comOrchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue EstimatesAugust 12, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOBIO, DRTS, CLPT, and NPCE Company DescriptionsClearPoint Neuro NASDAQ:CLPT$19.74 +0.46 (+2.39%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$19.60 -0.14 (-0.70%) As of 06:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Alpha Tau Medical NASDAQ:DRTS$4.16 +0.10 (+2.46%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$4.14 -0.02 (-0.50%) As of 06:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.NeuroPace NASDAQ:NPCE$10.01 -0.21 (-2.05%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$9.99 -0.02 (-0.15%) As of 06:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Orchestra BioMed NASDAQ:OBIO$2.43 +0.01 (+0.41%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$2.42 -0.02 (-0.62%) As of 09/25/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas It's a Good Time to Build a Position in KB Home Alphabet: Time to Take Profits, Buy, or Wait for a Pullback? Cintas Stock Sends a Clear Buy Signal as Momentum Builds Thor Industries Tracking for New Highs in 2026 Micron’s Stock Price Rally Is Not Over: MU $190 Is Coming Soon NuScale Power: The SMR Stock at the Heart of the AI Energy Boom Intel + NVIDIA: The Unexpected AI Alliance Shaking Wall Street Why Traders Are Doubling Down on SoundHound Stock After Big Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
